Stewart Lonky, MD
Pulmonary Disease · Los Angeles, CANPI 1033145941
Payments from drug & device makers
Across 63 payments — averaging $149.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$8K
- Boehringer Ingelheim$280
- Gilead$196
- Mallinckrodt Enterprises LLC$194
- AstraZeneca$123
- Harmony Biosciences LLC$100
- plus $327 from 6 others
What the payments were for
- Speaking & faculty fees$6,93074%
- Travel & lodging$93110%
- Food & beverage$1,42715%
- Education$1001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 17 | $8,169 |
| Boehringer Ingelheim | 7 | $280 |
| Gilead | 9 | $196 |
| Mallinckrodt Enterprises LLC | 9 | $194 |
| AstraZeneca | 6 | $123 |
| Harmony Biosciences LLC | 1 | $100 |
| Advanced Respiratory, Inc | 4 | $95 |
| Mallinckrodt Hospital Products Inc. | 3 | $94 |
| Actelion Pharmaceuticals US, Inc. | 3 | $66 |
| Mylan Specialty L.p. | 2 | $39 |
| Lilly USA, LLC | 1 | $18 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$7,797
- OFEV$122
How this compares
$9,388 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 11 | $2,020 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $657 |
| Ondansetron OdtOndansetron | 11 | $434 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $333 |
| Omeprazole | 34 | $329 |
| Montelukast Sodium | 16 | $263 |
| Metoprolol Succinate | 14 | $193 |
| Atorvastatin Calcium | 19 | $127 |
| Potassium Chloride | 14 | $101 |
| Azithromycin | 12 | $96 |
| Losartan Potassium | 14 | $59 |
| Amlodipine Besylate | 19 | $58 |
| Lorazepam | 11 | $58 |
| Tramadol Hcl | 19 | $54 |
| Furosemide | 23 | $49 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Andrew WachtelLos Angeles$5.9M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.